DEF 14A: Avalo Therapeutics Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting

Avalo Therapeutics is holding its annual stockholder meeting on August 13, 2024, to vote on the election of directors, approval of stock issuances, equity incentive plans, and other important matters.

Summary

• Avalo Therapeutics is convening its 2024 Annual Meeting of Stockholders on August 13, 2024, as a virtual event.
• Stockholders will vote on several proposals, including the election of seven directors, approval of common stock issuance related to preferred stock conversion and warrant exercises, approval of the Fourth Amended and Restated Equity Incentive Plan, approval of the Amended and Restated Employee Stock Purchase Plan, and ratification of Ernst & Young LLP as the company's independent auditor.
• The board of directors recommends voting in favor of all proposals.
• The record date for determining stockholders eligible to vote is June 17, 2024.
• The company outlines the voting procedures and the implications of not voting.
• The proxy statement also details information regarding the board's corporate governance practices, director compensation, executive compensation, and related person transactions.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The acquisition of AVTX-009 and the successful capital raise are positive, but the company's history of net losses and the risks associated with drug development temper the overall sentiment.

Positives

• The gross upfront funding of $115.6 million from the Private Placement is expected to fund operations into 2027, which includes through the topline data readout from Avalo's planned Phase 2 trial in HS, which is expected in 2026.
• The company has taken steps to strengthen its balance sheet, including raising $46.2 million from equity financings in 2023 and paying off its debt.
• The company has an experienced management team and research development team capable of developing a product candidate.
• The Board believes that the structure of the Acquisition, which included the issuance of Series C Preferred Stock and Warrants at a simultaneous sign and close of the Private Placement instead of a structure where our stockholders could vote to approve or disapprove of the Merger and the issuance of securities prior to the consummation of the Merger (Traditional Structure), had benefits to our stockholders.

Negatives

• The company has incurred significant net losses in most periods since its inception and expects to continue to incur net losses in the future.
• The company is not in compliance with the minimum stockholders equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1).
• The market price of the company's stock is volatile, and investors could lose all or part of their investment.
• The company relies on third parties to manufacture all of its product candidates, which may increase the risk of insufficient quantities or unacceptable costs.

Risks

• The company may not be able to successfully develop AVTX-009 and realize the benefits that it believes it offers.
• The company may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• The marketing approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, costly and inherently unpredictable.
• The company relies on third parties to conduct and monitor its clinical trials, and the failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially harm the company's business.
• The company expects to need additional capital in the future for the continued development of its product candidates and for its long-term operations, which might not be available to it on acceptable terms, or at all.

Future Outlook

The company expects the upfront funding of $115.6 million from the Private Placement to fund operations into 2027, including through the topline data readout from Avalo's planned Phase 2 trial in HS, which is expected in 2026.

Management Comments

• Avalo's management believes that AVTX-009 has a high probability of success for the treatment of HS as evidenced by recent data readouts validating inhibition of IL-1 in this disease.
• Avalo's management believes that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life, and potency, which may allow for strong efficacy and convenient dosing.

Industry Context

The announcement highlights Avalo's strategic shift towards immunology and its focus on AVTX-009, aligning with the growing interest in IL-1 inhibition for inflammatory diseases.

Comparison to Industry Standards

• The document mentions two drugs approved for hidradenitis suppurativa (HS), indicating a competitive landscape.
• The document mentions five BTLA agonist antibodies in clinical development for the treatment of autoimmune diseases, indicating a competitive landscape.
• The document mentions that AVTX-009 is one of three anti-IL-1 antibodies in clinical development worldwide, indicating a competitive landscape.

Related Party Transactions

• In November of 2022, Avalo closed a purchase agreement (the Asset Purchase Agreement) with ES Therapeutics, LLC (ES) for upfront proceeds of $5.0 million, pursuant to which the Company (i) sold to ES all of the Companys (a) rights to any milestone payments, under the Asset Purchase Agreement, dated August 14, 2017, by and between the Company and Janssen Pharmaceutics, Inc. (relating to AVTX-501), and (b) any future milestone and royalty payments under the License Agreement, dated July 29, 2022, by and between Apollo AP43 Limited and the Company (relating to AVTX-007), and (ii) waived all rights, including payments due to the Company from ES, under the Assignment of the License Agreement dated August 8, 2019 (relating to AVTX-611), by and among the Company, ES and Armistice Capital LLC (Armistice) (the ES Transaction).
• At the time of the ES Transaction, Armistice was a significant stockholder of the Company and whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalos Board until August 8, 2022.

Stakeholder Impact

• Approval of the stock issuance proposal could increase the company's market capitalization and provide liquidity for the common stock, potentially benefiting shareholders.
• The transactions are expected to provide Avalo with adequate resources to progress AVTX-009 through a Phase 2 data readout in HS, which the board believes is a critical inflection point for stockholders.

Next Steps

• Stockholders to vote on proposals at the Annual Meeting on August 13, 2024.
• The company to progress AVTX-009 through a Phase 2 data readout in HS.
• The company to seek Required Stockholder Approval to permit the issuance of Common Stock upon conversion of the Series C Preferred Stock and exercise of the Warrants, as well as the payment of the Milestones in shares of Common Stock.

Key Dates

Keywords

Avalo Therapeutics, stockholders meeting, directors, stock issuance, equity incentive plan, employee stock purchase plan, Ernst & Young, AVTX-009, AlmataBio, proxy statement